Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228915 · ClinicalTrials.gov registry record
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 21
- Enrollment target
NCT02228915 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 21 participants.
The verdict
NCT02228915 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The purpose of this research study is to discover and quantitate the differences in post-translational modifications found in the Cu, Zn superoxide dismutase (SOD1) of patients with amyotrophic lateral sclerosis (ALS) as compared to healthy individuals. SOD1 is a known genetic cause of ALS. With certain mutations, SOD1 gains a toxic function which leads to motor neuron death.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-10-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228915
The ClinicalTrials.gov registry entry for NCT02228915 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02228915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228915 about?
NCT02228915 is a clinical study titled "Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis". The purpose of this research study is to discover and quantitate the differences in post-translational modifications found in the Cu, Zn superoxide dismutase (SOD1) of patients with amyotrophic lateral sclerosis (ALS) as compared to healthy individuals. SOD1 is a known genetic cause of ALS. With cer...
What is the current status of trial NCT02228915?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2014-08. Estimated completion is 2018-10-16.
Who is sponsoring clinical trial NCT02228915?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.